{
}
Pharma giants are experiencing a slowdown in earnings growth, primarily due to their reliance on the US generics market and a lack of major drug launches. Companies like Cipla, Dr Reddy's, and Aurobindo Pharma face challenges from rising competition and impending patent expirations, while midcap firms focused on the domestic market continue to thrive without the same pressures.
Spiriva
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
pharma sector faces growth slowdown while domestic market thrives
United States Dollar
Aurobindo Pharma Limited
SBI Life Insurance Company Ltd.
Cipla Limited
DR Reddy'S Laboratoire Ltd.
TVS Motor Company Limited
HUL
Lupin Limited
IND
Lupin
Spiriva
Cipla
Dr Reddy's
Aurobindo Pharma
Show more
05:31 25.10.2024
Trending
Subcategory
AI Innovations
Corporate News
Stock Market Updates
Industry Trends
Market Analysis and Predictions
Startups & Entrepreneurship
Banking Regulations
Emerging Startups
Cybersecurity Innovations & Tech
Funding Rounds & Investments
Product Launches
Economic Indicators
Fintech Startups
Private Equity Deals
Software Development Trends
Venture Capital Investments
Retail and Consumer Goods
Industry Mergers & Acquisitions
AI Applications
Finance Mergers & Acquisitions
Countries:
Companies:
Huawei Technologies CO. Ltd.
UBS Group AG
NVIDIA Corporation
Nvidia Corporation
Apple Inc.
Google Inc.
Microsoft Corporation Corp.
Berner Kantonalbank AG
Deutsche Bank AG
Crane Company
Deyaar Development PJSC
Maverick Ventures (Israel) 1.5 GP Ltd.
SuperSeed B.V.
DeepSeek R1 USD
Tencent Holdings Limited
XPeng Inc.
Toyota Motor Corporation
Alphabet Inc.
Xiaomi Corporation
NEO-NEON
Currencies:
United States Dollar
Euro
Chinese Yuan
Swiss Franc
Indian Rupee
British Pound Sterling
Japanese Yen
South African Rand
Filipino Peso
Norwegian Krone
Offshore Chinese Yuan
People: